Previous 10 | Next 10 |
To ensure your vote is counted, shareholders are encouraged to vote their GREEN Proxy today in advance of the voting deadline of Friday, June 21, 2019 at 5:00 p.m. (MST) Questions? Need help? Contact call Gryphon Advisors Inc. at: 1-833-266-0365 or at inquiries@gryphonadvisors.ca . ...
ISS and Glass Lewis Recommend Aurinia Shareholders Not Support ILJIN’s Nominees Highlight Aurinia’s Strong Track Record of Shareholder Value Creation Note ILJIN has Failed to Make a Compelling Case for Change Leading independent proxy advisory firms Institution...
Details Aurinia’s Underperformance Resulting from Poor Governance Practices, Bloated Compensation, CEO Turnover and Conflicts of Interest under Incumbent Board Shareholders Urged to Vote Their GREEN Proxy or GREEN VIF to Strengthen Board with Three New, Highly Qualified Independent...
Shareholders Urged to Vote Their GREEN Proxy or GREEN VIF to Strengthen Board with Three New, Highly Qualified Independent Nominees ILJIN SNT Co., Ltd. (“ ILJIN ”) today sent a letter to shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (“ Aurinia ...
Highlights the Company’s strong progress, advancement of voclosporin, and value creation for all shareholders Notes recent Board refreshment, deep expertise in drug commercialization Believes ILJIN has offered no plan for value creation Corrects ILJIN’s mis...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the following upcoming investor conferences: Jefferies Healthcare Conference on Friday, June 7, 2...
Three Independent Directors Nominated to Strengthen Board, Remove Conflicts and Return Control of the Company to Shareholders Commercial Potential of Voclosporin is Tremendous, But Not Reflected in the Company’s Share Price Under Current Leadership Current Group of Hand-Picked a...
- Special Committee of the Board and Management urges you to vote your shares using the YELLOW proxy - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Cir...
Market Assessment ChemoCentryx ( CCXI ) is a clinical-stage small market cap ($683M) biopharma developing innovative therapeutics predominantly for kidney diseases. Its scientific forte is chemokine biology. This is not surprising since Thomas Schall, PhD, the founder of ChemoCentryx, is a...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...